Global Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecast 2016-2027 - | Financial Buzz

Global Neuroendocrine Tumors (NETs) Market Insights, Epidemiology and Market Forecast 2016-2027 –

The “Neuroendocrine
Tumors (NETs) – Market Insights, Epidemiology and Market Forecast-2027”
drug pipelines has been added to’s

The market of Neuroendocrine Tumors in 7MM was found to be USD 3.45
billion in 2016.

Neuroendocrine Tumors (NETs) – Market Insights, Epidemiology and Market
Forecast-2027 report delivers an in-depth understanding of the disease,
historical & forecasted epidemiology as well as the market trends of
NETs in the United States, EU5 (Germany, Spain, Italy, France and United
Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs
having the potential to get launched in the forecast period, market
share of the individual therapies, current and forecasted market size of
Neuroendocrine Tumors from 2016 to 2027 segmented by seven major
markets. The Report also covers current treatment practice/algorithm,
market drivers, market barriers and unmet medical needs to curate best
of the opportunities and assess underlying potential of the market.

This segment of the NETs report encloses the detailed analysis of
marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
It also helps to understand the clinical trial details, expressive
pharmacological action, agreements and collaborations, approval and
patent details, advantages and disadvantages of each included drug and
the latest news and press releases.

Detailed chapter for upcoming therapies like Azedra (Progenics
Pharmaceuticals), 177Lu-edotreotide PRRT (ITM Isotopen Technologien
Muenchen), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001
(EpicentRx), Entrectinib (Ignyta), AMG-479 (Amgen), Carfilzomib (Amgen),
ATG-008 (Antengene) and Fosbretabulin (Mateon Therapeutics) have been
covered in the report.

Key Topics Covered:

1. Key Insights

2. Neuroendocrine Tumors Epidemiology Overview at a Glance

3. Disease Background and Overview: Neuroendocrine Tumors (NET)

4. Epidemiology and Patient Population

5. Treatment Algorithm

6. Unmet needs

7. Marketed drugs

8. Emerging drugs

9. Key Cross Competition

10. Neuroendocrine Tumors: 7 Major Market Analysis

11. Market Drivers

12. Market Barriers

13. Appendix

Companies Mentioned

For more information about this drug pipelines report visit

View source version on